Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company, has reported a recent insider transaction. According to a filing with the Securities and Exchange Commission, ...
Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company that has delivered an impressive 11.7% return year-to-date, reported a stock sale by Chief Financial Officer Matt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback